Richard Bertz

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results

Robert L. Murphy, Scott Brun, Charles B. Hicks et al. · AIDS · 2001 · 239 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

C. J. L. la Porte, E. P. H. Colbers, Richard Bertz et al. · Antimicrobial Agents and Chemotherapy · 2004 · 185 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

Ann Hsu, Jeffrey D. Isaacson, Scott Brun et al. · Antimicrobial Agents and Chemotherapy · 2002 · 149 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

Xavier Sáez‐Llorens, AVYI VIOLARI, Carl O. Deetz et al. · The Pediatric Infectious Disease Journal · 2003 · 142 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial

Joseph J. Eron, Judith Feinberg, Harold A. Kessler et al. · The Journal of Infectious Diseases · 2004 · 123 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13